CSIMarket Company Name, Ticker, Suppliers, else..
 

Lineage Cell Therapeutics Inc   (NYSE: LCTX)

Lineage Cell Therapeutics Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

LCTX Sales vs. its Competitors Q2 2026


Comparing the current results to its competitors, Lineage Cell Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -61.34 %, faster than the overall decrease of Lineage Cell Therapeutics Inc 's competitors by 0 %, recorded in the same quarter.

• List of LCTX Competitors

With a net margin of 144.43 % Lineage Cell Therapeutics Inc reported lower profitability than its competitors.

• More on LCTX Profitability Comparisons



Revenue Growth Comparisons




Net Income Comparison

Lineage Cell Therapeutics Inc achieved net profit of $1.54 millions compared to a net loss of $-30.36 millions recorded in the same quarter a year ago.

<<  LCTX Stock Performance Comparisons


Lineage Cell Therapeutics Inc 's Comment on Competition and Industry Peers


Lineage has completed current Good Manufacturing Practice (cGMP) production runs for product candidates and utilized these in FDA-cleared clinical trials, capabilities not commonly achieved by competitors. The company’s AlloSCOPE platform and novel gene edits, including HLA-E overexpression, are designed to provide clinical differentiation. Lineage collaborates with Factor, which supplied a novel induced pluripotent stem cell (iPSC) line with potential for exclusive licensing. The company recognizes risks related to patent filings and potential litigation from competitors who may hold patents that could block or compete with its products. Lineage faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, research institutions, existing standard-of-care treatments, and new therapies in development.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Lineage Cell Therapeutics Inc




Avalon Globocare Corp
Share Performance



-45.94%
This Quarter
Avalon Globocare Corp
Profile

Avalon Globocare Corp's business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.

More about Avalon Globocare Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.172 mill. $ - mill. $ -8.979 mill.


Vericel Corporation
Share Performance



+12.94%
One Year
Vericel Corporation
Profile

Vericel Corporation's business model revolves around the development and commercialization of innovative cellular therapies for the treatment of severe diseases and conditions.

More about Vericel Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,922.774 mill. $ 292.086 mill. $ 21.462 mill.


Instil Bio Inc
Share Performance



-69.08%
One Year
Instil Bio Inc
Profile

Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.

More about Instil Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 49.915 mill. $ 8.968 mill. $ -30.281 mill.


Senti Biosciences Holdings Inc
Share Performance



-12.22%
Over The Past 5 Days
Senti Biosciences Holdings Inc
Profile

Senti Biosciences Inc is a biotechnology company that develops and commercializes novel therapeutics using synthetic biology and gene editing technology.

More about Senti Biosciences Holdings Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9.350 mill. $ 0.055 mill. $ -49.564 mill.


Mesoblast Limited
Share Performance



-8.39%
30 Days
Mesoblast Limited
Profile

Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.

More about Mesoblast Limited's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ 17.198 mill. $ -102.142 mill.

6 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Lineage Cell Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lineage Cell Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.